DD — DuPont de Nemours, Inc.

The tape and the sell-side are pulling in opposite directions. The tape is clearly negative: as of 2026-09-13 the stock was -6.18% vs its 20-day SMA, -7.74% vs the 50-day, -7.27% vs the 200-day, with a -3.5% week, -12.04% month, -12.29% three-month and -5.72% six-month return and RSI at 29.16 - a broken uptrend, not a range. Nothing in the recent news justifies it: on 2026-08-04 DuPont beat with Q2 revenue of $1.82B (+4% organic) and adjusted EPS of $1.88 vs $1.76 consensus, posted $448M operating EBITDA (24.6% margin) at 127% free-cash-flow conversion, and raised FY26 adjusted EPS guidance to ~$7.24-$7.32. It also settled long-running PFAS claims with North Carolina and 11 local entities on 2026-09-10, announced a $250M Q3 buyback, and changed GICS classification to Industrials effective 2026-07-31. That last item is my best guess at the mechanical culprit: a sector reclassification forces Materials-sector funds to sell and Industrials mandates/index funds to buy, and that flow mismatch - plus macro caution into late-summer central bank meetings - can easily produce a 12% air-pocket with no fundamental deterioration. Sell-side sentiment remains constructive (roughly 24 Buys vs 1 Sell in the FMP breakdown), so the divergence is 'market bearish, analysts bullish'.

The reported 3-year trend is dominated by a structural break, not an operating one. The legacy company ran revenue of $2.9-$3.3B per quarter from Q3 2023 through Q3 2025 with operating income of $355-547M; then revenue collapsed from $3,072M (2025-09-30) to $1,693M (2025-12-31), a -45% sequential drop that lines up with the Electronics separation and Aramids divestiture, not demand. GAAP earnings through that transition were a mess: -$589M in Q1 2025, +$59M in Q2 2025, -$123M in Q3 2025, -$126M in Q4 2025. On the two clean post-spin quarters the picture is genuinely improving: Q1 2026 revenue $1,681M with $186M operating income (11.1% margin) and $161M GAAP net income ($1.17 EPS), then Q2 2026 revenue $1,819M (+8.2% QoQ) with $256M operating income (14.1% margin, +300bp QoQ) and $143M net income ($1.05 EPS, versus $1.88 adjusted). GAAP profitability has now inflected positive for two consecutive quarters after five quarters of spin/divestiture-driven losses. Cash is confirming it: H1 2026 operating cash flow of $553M against $178M capex for $375M of free cash flow, including $245M in Q2 alone versus $224M in the year-ago quarter on a revenue base 44% smaller - that is real conversion improvement, and the deterministic score's own accruals ratio of -0.85% (as of 2026-06-30) says cash is running slightly ahead of reported earnings, the healthy direction. Verdict: the revenue decline is structural/portfolio and permanent; the margin and earnings recovery is recent, sequential, and - with only two clean quarters - not yet proven, but it is an inflection rather than a blip.

Every trailing multiple in the FMP file is unusable and should be ignored: TTM P/E 275.96, PEG -0.147, EPS TTM $0.404, net margin 0.7%, ROE -5.6% - all artifacts of spinoff charges and a shrinking legacy earnings base, not economics. On forward numbers, DD at $126.94 is 17.4x the FY26 adjusted EPS guidance midpoint of $7.28 and roughly 10.5x FY26E EBITDA of about $1.76B (annualizing Q2's $448M at a 24.6% margin against ~$18.5B EV after ~$1.4B net debt). Those are fair, not cheap, multiples for a 4%-organic-growth specialty materials company with 24.6% EBITDA margins and sub-1x net leverage - a premium name like Ecolab or Xylem commands more, a cyclical industrial commands less. Versus its own history, the FMP 5-year average P/E of 14.63 and P/S of 1.46 make the current 17.4x forward P/E and 2.07x sales look rich, which is exactly why the deterministic engine tags this 'Rich vs. its own history' - but that history belongs to a pre-spin conglomerate carrying a PFAS overhang and a conglomerate discount that no longer exists, so I weight it lightly. Balance sheet and yield are supportive: 1.26x book, 0.227 debt/equity, 2.43 current ratio, 1.78% dividend yield on a ~31% payout. Bottom line: fair-to-slightly-full on clean earnings, cheap-to-fair on EV/EBITDA, with no valuation cushion to rescue a guidance miss.

The important tell here is that price fell ~12% over the last month while estimates went UP - that is multiple compression, not estimate cuts, which usually means the market is discounting something other than the earnings stream (sector-rotation flow from the 2026-07-31 GICS move to Industrials, rate/macro caution, or lingering spinoff-complexity discount). That setup can mean the gap closes quickly if Q3 confirms guidance. But apply a discount to the headline numbers: Q2 GAAP EPS was $1.05 versus $1.88 adjusted, and H1 GAAP EPS totaled only $2.22 against a full-year adjusted guide of $7.24-$7.32, meaning a large share of the 'beat' comes from add-backs (intangibles amortization, restructuring, spin costs). A beat on adjusted EPS is worth less than it looks; the harder evidence in the quarter was the $245M of free cash flow and the 127% conversion. So the playbook is: track free cash flow and organic growth, not the adjusted EPS headline, and note that FMP's own price-target field is contradictory and unreliable - it shows a $97 consensus with a $115.50 recent average from only 2 analysts, while the live brief cites an average target of $166.60-$171.00. I would not use either as an anchor.

As of 2026-09-13, RSI(14) was 29.16 - oversold - and the price of $126.94 sat 6.18% below the 20-day SMA, 7.74% below the 50-day and 7.27% below the 200-day, with the 200-day also above the shorter averages. That is a broad downtrend with no base, not a range. The stock is only a little above the midpoint of its $92.49-$157.98 52-week range, so it is not washed out in absolute terms. Implication for timing: oversold readings inside a downtrend are notoriously unreliable entry signals, and there is no confirmation of a bottom yet. Momentum/quant funds that sell on moving-average breaks are still in sell mode, and the GICS-related rebalancing flow may not be finished. A patient buyer would want to see RSI reclaim roughly 45-50 and the price reclaim the 20-day (near $135 by mid-September arithmetic) before treating this as a trend change; an oversold bounce off $120-125 is plausible but should not be mistaken for a reversal. These are point-in-time figures from 2026-09-13 and will be stale in weeks, not months.

• Interest rates and central bank posture: a 4%-organic-growth compounder is duration-sensitive, and high rates both compress its multiple and raise the financing cost of the $1B+ bolt-on M&A war chest management has flagged for healthcare packaging.
• Index and sector-flow mechanics: the 2026-07-31 GICS reclassification from Materials to Industrials forces sector funds and index trackers to rebalance, creating forced supply that has nothing to do with fundamentals - a plausible driver of the recent 12% drawdown.
• Water infrastructure and biopharma capex: global water upgrades (RO membranes, ion exchange) and bioprocessing consumables are multi-year structural tailwinds for the post-spin portfolio, though Middle East water project timing delays are already a documented headwind management had to offset with healthcare strength.
• Chemical regulation and PFAS/ESG scrutiny: the 2026-09-10 North Carolina settlement removes one large overhang, but state and federal environmental compliance costs and any remaining claimant jurisdictions stay in the institutional risk model.
• Global industrial demand cycle: Industrial Technologies (specialty films and consumables) is levered to manufacturing PMIs, and a weak global industrial backdrop is the single biggest threat to the 'above 4% organic' full-year target.

• Q3 2026 earnings on 2026-11-10: guidance is $1.80-$1.90 EPS on ~$1.835B sales; a third consecutive beat would validate the raised FY26 $7.24-$7.32 range and could close the multiple-compression gap.
• Capital deployment: completion of the $250M Q3 buyback authorization plus progress on the $1B+ earmarked for healthcare-packaging bolt-ons - accretive M&A would be a re-rating trigger.
• PFAS de-risking after the 2026-09-10 North Carolina and 11-entity settlement: any further jurisdictional settlements or finalization details reduce the tail liability that has historically kept a discount on the shares.
• Margin trajectory: sustaining Q2's 24.6% adjusted EBITDA margin and building toward the high-20s would justify a multiple closer to water/pure-play specialty peers.
• Normalization of index/flow dynamics once the Industrials reclassification rebalancing is complete, which would remove a non-fundamental source of selling.

• The adjusted-versus-GAAP gap: Q2 2026 GAAP EPS was $1.05 against $1.88 adjusted, and H1 GAAP EPS of $2.22 versus a $7.24-$7.32 full-year adjusted guide means heavy recurring add-backs (amortization, restructuring, spin costs). 'Beats' on this basis may overstate true economic earnings.
• Organic growth of only ~4% with documented Middle East water project timing delays and soft industrial demand - a miss on the guidance raise would be punished hard given the stock is not cheap on forward earnings.
• Residual PFAS and environmental liability beyond the 2026-09-10 North Carolina settlement, which resolves NC and 11 local entities but not every jurisdiction or claimant class.
• Broken technicals with no base: price below the 20/50/200-day averages and RSI at 29 as of 2026-09-13 means momentum-driven selling can continue well past the point where value buyers step in.
• Execution risk in a freshly reshaped portfolio: only two clean post-spin quarters, a GICS reclassification in July 2026, and bolt-on M&A to integrate, all with a short track record for the new DuPont.

This is a better business than its trailing statements make it look and a worse bargain than its bulls imply. Post-spin DuPont is a 24.6%-EBITDA-margin specialty materials company with healthcare and water end markets growing ~4% organically, ~$1.4B net debt against ~$1.76B EBITDA (under 1x leverage), a 1.78% dividend and a recent major litigation overhang resolved - trading at 17.4x clean FY26 adjusted EPS and ~10.5x EV/EBITDA. My math puts fair value near $146, so there is real but moderate upside, not the 30%+ the sell-side targets imply. Against that: a wide GAAP-to-adjusted earnings gap, 4% growth that is not obviously accelerating, a 'rich versus its own history' tag, and a downtrend with RSI at 29 and no base. I would not chase it here, but it belongs on a watchlist - the risk/reward improves materially on a technical base or after the 2026-11-10 print confirms the guidance.

I applied 20.0x to FY2026 adjusted EPS of $7.30 (the $7.24-$7.32 guidance midpoint) for $146, and cross-checked it with an EV/EBITDA approach: 12.0x FY2026E EBITDA of ~$1.76B (annualizing Q2 2026's $448M at a 24.6% margin) gives a $21.1B enterprise value, less ~$1.4B net debt ($3.13B long-term debt against $1.74B cash) leaves ~$19.7B equity, or ~$146 per share on the ~135M diluted shares implied by the $143M Q2 net income / $1.05 EPS. The 20x P/E is justified as a modest premium to DD's pre-spin 14.63x average (that multiple reflected a conglomerate discount and PFAS overhang that the 2026-09-10 settlement and portfolio pruning have largely removed) but a discount to premium water/biopharma specialty peers, appropriate for a 24.6%-margin, sub-1x-levered business growing ~4% organically.